- Check Our Services
An Overlooked Cause of Heart Failure
Details
READING TIME
3 min
CATEGORY
Blog
AUTHOR
John Dawod
TOPIC
Amyloidosis Africa
Cardiac Amyloidosis in Africa: An Overlooked Cause of Heart Failure
Heart failure is an increasingly common health challenge across Africa. In many countries, clinicians frequently attribute heart failure to hypertension, coronary artery disease, or cardiomyopathies. However, another important and often overlooked cause of heart failure is cardiac amyloidosis.
Cardiac amyloidosis occurs when abnormal proteins called amyloid accumulate in the heart muscle. These deposits cause the heart walls to become thick and stiff, eventually impairing the heart’s ability to pump blood effectively. Although awareness of this condition has increased globally, cardiac amyloidosis in Africa remains significantly underdiagnosed, leading to delayed treatment and poorer outcomes for patients.
Improving recognition of cardiac amyloidosis among healthcare professionals is essential to ensure earlier diagnosis and better care for patients across the continent.
Understanding Cardiac Amyloidosis
Cardiac amyloidosis is a disease characterized by the deposition of misfolded proteins in the heart tissue. These protein deposits gradually disrupt the normal structure and function of the heart muscle.
As amyloid accumulates, the heart walls become rigid and less able to relax during filling. This leads to a form of heart failure known as restrictive cardiomyopathy. Patients often experience symptoms such as fatigue, shortness of breath, and leg swelling.
Two major types of cardiac amyloidosis are particularly important in clinical practice.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
ATTR cardiomyopathy results from instability of the transthyretin protein produced by the liver. When this protein misfolds, it forms amyloid fibrils that deposit in the heart.
ATTR-CM occurs in two forms:
Wild-type ATTR (wtATTR)
This form usually affects older adults and is associated with age-related changes in the transthyretin protein.
Hereditary ATTR (hATTR)
This form is caused by genetic mutations in the transthyretin gene. Certain mutations have been identified in populations around the world and may also be present in African populations.
ATTR cardiomyopathy is increasingly recognized as a significant cause of heart failure with preserved ejection fraction (HFpEF).
Light-Chain Amyloidosis (AL Amyloidosis)
AL amyloidosis is caused by abnormal plasma cells that produce misfolded immunoglobulin light chains. These proteins circulate in the bloodstream and deposit in organs such as the heart, kidneys, and nerves.
Unlike ATTR amyloidosis, AL amyloidosis can progress rapidly and requires urgent diagnosis and treatment.
Why Cardiac Amyloidosis Is Often Missed in Africa
Despite growing awareness globally, cardiac amyloidosis remains underrecognized in many African healthcare settings. Several factors contribute to this diagnostic gap.
Limited Awareness Among Healthcare Providers
Many clinicians receive little formal training on amyloidosis during their medical education. As a result, cardiac amyloidosis may not be considered when evaluating patients with unexplained heart failure.
Consequently, patients may receive alternative diagnoses such as hypertensive heart disease or dilated cardiomyopathy.
Symptoms Overlap With Common Diseases
Cardiac amyloidosis often presents with symptoms that mimic other cardiovascular conditions. Patients frequently experience:
Shortness of breath
Fatigue
Exercise intolerance
Swelling of the legs
Because these symptoms resemble typical heart failure, the underlying cause may remain unidentified.
Limited Access to Specialized Diagnostic Tests
Confirming the diagnosis of cardiac amyloidosis often requires advanced diagnostic tools, including:
Nuclear scintigraphy imaging
Cardiac magnetic resonance imaging (CMR)
Serum-free light chain testing
Genetic testing
In many African healthcare systems, these tests may be unavailable or limited to specialized referral centers.
Lack of Epidemiological Data
Another major challenge is the scarcity of data on amyloidosis in African populations. Without national registries or research programs, the true prevalence of cardiac amyloidosis in Africa remains largely unknown.
This lack of data contributes to the perception that amyloidosis is extremely rare on the continent.
Clinical Red Flags for Cardiac Amyloidosis
Although cardiac amyloidosis can resemble other forms of heart disease, several clinical features may suggest the diagnosis.
Heart Failure With Preserved Ejection Fraction
Patients with heart failure symptoms and thickened ventricular walls on echocardiography should raise suspicion, especially when hypertension alone cannot explain the findings.
Discrepancy Between ECG and Echocardiography
A common diagnostic clue is low voltage on ECG despite increased ventricular wall thickness on echocardiography.
Bilateral Carpal Tunnel Syndrome
Carpal tunnel syndrome occurring years before heart failure symptoms may be an early sign of transthyretin amyloidosis.
Peripheral Neuropathy or Autonomic Dysfunction
Symptoms such as numbness, tingling, dizziness when standing, or gastrointestinal disturbances may indicate systemic amyloid involvement.
Recognizing these warning signs can help clinicians identify patients who require further evaluation.
Why Early Diagnosis Matters
Early diagnosis of cardiac amyloidosis is critical because treatments are now available that can significantly improve outcomes.
Recent advances in medicine have led to the development of therapies that:
Stabilize transthyretin proteins
Reduce the production of abnormal proteins.
Target amyloid deposits in tissues
However, these treatments are most effective when started early in the disease course.
Delayed diagnosis may allow irreversible organ damage to occur, reducing treatment effectiveness and worsening prognosis.
Strengthening Awareness and Diagnosis in Africa
Improving recognition of cardiac amyloidosis in Africa requires coordinated efforts across several areas.
Medical Education
Training programs and continuing medical education initiatives can help clinicians recognize the early signs of amyloidosis and understand diagnostic pathways.
Diagnostic Capacity
Expanding access to echocardiography, nuclear imaging, and laboratory testing will significantly improve diagnostic accuracy.
Research and Registries
African-led research initiatives and disease registries are essential for understanding the prevalence and clinical characteristics of amyloidosis in African populations.
Regional Collaboration
Collaboration between cardiologists, neurologists, nephrologists, and researchers across Africa can accelerate progress in diagnosis and treatment.
Pan-African networks can facilitate multicenter studies, share clinical expertise, and promote standardized care pathways.
The Role of Awareness Initiatives
Initiatives that promote awareness of amyloidosis among healthcare professionals and the public are crucial.
Educational campaigns, medical conferences, and research collaborations can help ensure that cardiac amyloidosis becomes part of routine diagnostic thinking when evaluating patients with unexplained heart failure.
Organizations and networks dedicated to amyloidosis awareness can play an important role in strengthening knowledge, building research capacity, and improving patient care across the continent.
Conclusion
Cardiac amyloidosis is an important but frequently overlooked cause of heart failure in Africa. Limited awareness, diagnostic challenges, and the lack of local research data have contributed to underdiagnosis across many healthcare systems.
However, increasing global recognition of amyloidosis provides an opportunity to improve detection and treatment.
By strengthening awareness, expanding diagnostic capacity, and supporting African research initiatives, healthcare systems across the continent can improve outcomes for patients affected by this disease.
Recognizing cardiac amyloidosis earlier will ultimately save lives and transform the future of heart failure care
Causes
Pan-African Research Collaboration
Quality Improvement & Impact
Documents
We advance cardiac amyloidosis care across Africa through collaboration, training, and research. Join us to change the future of heart health and empower local clinicians with knowledge and tools.
- Support cardiac care in Africa
- Give what you can to help
- Join our research network!
- Follow updates and news
